DSIP (Delta Sleep-Inducing Peptide)

What the Field Said After Its First Decade

UKPWritten and published by UK Peptides2 min readUpdated 2 cited sources

The short answer

Graf published an update on delta sleep-inducing peptide in Peptides in 1986, nine years after the original report. Reviews written mid-literature are useful because they record what the field expected next.

Key facts

Review
Graf 1986 (PMID 3550726)
Journal
Peptides, Nov-Dec 1986
Years after discovery
Nine
Author
Also co-author of the 1984 tissue work
Value of mid-literature reviews
They record expectations
What followed
No gene, no receptor

Why a nine-year update is a useful document

A review written at the point where a field still expects resolution captures something later accounts cannot. It records what was thought to be nearly settled and what was expected imminently. Comparing that against what actually followed is a direct measure of how a research programme went.

Where the field stood at that point

The sequence was known, synthesis was routine, immunoassays existed, and distribution had been mapped across brain and peripheral tissue. That is a substantial platform, and by the ordinary progression it should have been followed by receptor identification and then a gene. Neither arrived.

Research material referenced

DSIP 5mg, third-party HPLC tested

Buy DSIP · £13.95

What the same author had already reported

Graf was a co-author of the 1984 work showing that peripheral immunoreactive material was mostly larger than DSIP. So the complication was known to the person writing the update. This was not a field unaware of its own difficulties, a point to keep in mind given how often the sceptical case is presented as hindsight.

Why the receptor never arriving is decisive

A receptor gives a field binding assays, dose-response relationships, selective antagonists and a target. Without one, an observed effect cannot be attributed to a pathway, and forty further years of work has not supplied it. This site makes the same point about MOTS-c, Selank and Semax, and DSIP is the longest-running instance.

How to read old reviews generally

As evidence about the state of a field at a date, not as current summaries. A 1986 review is accurate about 1986. Citing it as though it described the present position, which happens with compounds whose literature peaked decades ago, misrepresents both the review and the field.

Regulatory position

DSIP holds no marketing authorisation anywhere, and no claim is made here about sleep or any condition in any person. Material supplied is for laboratory research only.

Frequently asked questions

Why read a 1986 review?

It records what the field expected next, which can be compared against what actually followed: a direct measure of how the programme went.

Was the field aware of the immunoassay problem?

Yes. Graf co-authored the 1984 work showing peripheral immunoreactive material was mostly larger than DSIP.

What never arrived?

A receptor and a gene. Without a receptor there is no way to attribute an observed effect to a pathway.

Continue researching

Related guides and reference material.

Primary sources & clinical trials

Published papers, trial registrations, regulator pages and company announcements. Links open the original.

Browse the wider literature

Live database searches, not fixed citations. Results change as new work is indexed.

UKP

Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).

Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.

Corrections log

More DSIP (Delta Sleep-Inducing Peptide) articles

Research use only. The information above is provided for scientific and educational reference. Compounds referenced are not approved for human use and are supplied for in vitro research or reference-material purposes only. No efficacy, safety, or therapeutic claims are made.